Table 1. Patients’ characteristics.
| Parameter | Cohort 1(n = 40) | Cohort 2(n = 182) | ||
|---|---|---|---|---|
| PVTT(n = 20) | No-PVTT(n = 20) | P value | ||
| Gender, male/female | 18/2 | 17/3 | 0.904 | 155/27 |
| Age, years, mean±SD | 50.4±7.5 | 53.9±9.3 | 0.24 | 53.1±10.5 |
| Hepatitis B, n (%) | 17(85) | 18(90) | 0.697 | 159 (87) |
| Child-pugh stage (A/B/C) | 18/2/0 | 19/1/0 | 0.737 | 163/19/0 |
| BCLC (B/C) | 0/20 | 20/0 | 0.000 | 98/84 |
| Treatment | ||||
| Local therapy, n (%) | 20(100) | 20(100) | 1 | 177(97.3) |
| Sorafenib, n (%) | 1(5) | 0(0) | 0.317 | 33(18.1) |
| Laboratory results | ||||
| TBIL (umol/L), mean±SD | 17.7±9.46 | 15.7±6.1 | 0.856 | 18.3±12 |
| DBIL(umol/L), mean±SD | 8.1±6.1 | 5.5±3.9 | 0.083 | 7.0±7.2 |
| ALT (IU/L), mean±SD | 72.6±103.2 | 39.8±22.5 | 0.338 | 47.5±50.4 |
| AST (IU/L), mean±SD | 65.5±38.3 | 50.2±31.4 | 0.062 | 61.1±64.2 |
| γ-GGT (IU/L), mean±SD | 167.9±75 | 149.9±188.6 | 0.053 | 174.5±198.0 |
| LDH (IU/L), mean±SD | 268.3±117.8 | 207.3±97.3 | 0.086 | 240.4±146.6 |
| ALP (IU/L), mean±SD | 180.5±157.4 | 125.6±76.5 | 0.104 | 146.3±113.6 |
| ALB (g/L), mean±SD | 38.1±4 | 39.8±4.9 | 0.057 | 39.2±4.6 |
| AFP (ng/ml), mean±SD | 3011±1230 | 1089±1556 | 0.000 | 1415±1615 |
| Median OS (95% CI), days | 289.5(242.2, 446.9) | 541.5(395.2, 829.3) | 0.013 | 525.6(466.2,585) |